PHIO PHARMACEUTICALS CORP (PHIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.08-2.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PHIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PHIO — earnings in line
Dated 2026-08-06
and attached as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Why it matters: This step is key for moving PH-762 closer to being sold.
Supportive ifPhio says it has finished making API at a commercial scale.
Worry ifPhio delays or fails to complete the commercial scale API by year-end 2026.
Why it matters: This meeting will clarify next steps for PH-762's clinical development. It is critical for future progress.
Supportive ifPhio submits a formal request to the FDA for a meeting regarding PH-762.
Worry ifPhio does not request the FDA meeting as planned in Q3 2026.
Why it matters: A drop in cash reserves could impact Phio's ability to fund operations beyond 2027.
Worry ifCash and cash equivalents fall below $10 million.
Less concerning ifCash and cash equivalents remain above $10 million.
Why it matters: The results will show how safe and effective PH-762 is.
Watch forPhio announces positive outcomes from the Phase 1b trial for PH-762.
Also watch forPhio reports negative outcomes or safety concerns from the Phase 1b trial.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$192 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $691 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,545 loss on $10,000 · 65.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Adding skilled members helps the company run better. It improves governance and strategy.
Supportive ifNew board members will know about dermatology or clinical work. They bring valuable experience.
Worry ifNo new board appointments are made in the next six months.
Why it matters: Cash reserves are key for operations until 2027. If they drop below $21.3 million, it raises concerns.
Worry ifManagement says cash reserves are at or above $21.3 million.
Less concerning ifCash reserves are below $21.3 million.
Why it matters: A drop below this level could indicate financial strain. It may affect the company's ability to fund operations.
Worry ifPhio reports cash and cash equivalents below $10 million in future filings.
Less concerning ifCash and cash equivalents remain above $10 million in future reports.
Why it matters: Cash reserves are important for keeping operations running. A big drop could hurt funding for projects.
Worry ifCash reserves stay steady or grow, helping operations into the second half of 2027.
Less concerning ifCash reserves fall a lot. This raises worries about funding after 2026.
Why it matters: Finishing this study is important for PH-762. It may help show it is safe.
Supportive ifThe long toxicology study will finish by the end of 2026.
Worry ifThe non-clinical toxicology study is not done by the end of 2026.
Why it matters: Big operating losses may mean management struggles with costs. This can worry investors about future success.
Worry ifOperating losses reported worse than -$4 million in the next quarter.
Less concerning ifOperating losses are -$4 million or less.
Why it matters: Sending the trial data is key for clinical development. It could affect investor trust.
Supportive ifFinal clinical study documents will be sent to the FDA.
Worry ifThere is a delay in sending the clinical study documents to the FDA.
Why it matters: The earnings report will provide updates on cash flow and operating losses. This is key for understanding financial health.
Watch forEarnings report shows better cash flow or smaller operating losses.
Also watch forEarnings report shows worse cash flow or larger operating losses.
Why it matters: Having cash reserves is key. It helps pay for clinical trials and operations.
Supportive ifPhio shows cash and cash equivalents are stable or growing, proving it can operate.
Worry ifPhio shows a big drop in cash reserves, which may mean funding problems.